31 results
Page 2 of 2
8-K
EX-99.1
dz8ibmxn9xam25
12 Aug 14
Company announces successful End-of Phase 2 meeting with the FDA and Phase 3 plans for ITI-007 for schizophrenia
12:00am
8-K
v67qz0419 yhh56mroo
7 Apr 14
Other Events
12:00am
8-K
EX-99.1
1dxr1787efj6 99z
7 Apr 14
Other Events
12:00am
424B3
ii0vo3ysl379qi
7 Apr 14
Prospectus supplement
12:00am
424B3
3lhlpojweepc
4 Apr 14
Prospectus supplement
12:00am
424B1
jw9z1aizqf6h in5p
31 Jan 14
Prospectus with pricing info
12:00am
424B3
et5n3n q6bfc608zv
19 Dec 13
Prospectus supplement
12:00am
8-K/A
gpzkxv61lj88
31 Oct 13
Entry into a Material Definitive Agreement
12:00am
S-1
de9waxwb sfi
18 Sep 13
IPO registration
12:00am
8-K
zy4z ffslw70tbr
5 Sep 13
Report of Independent Registered Public Accounting Firm
12:00am